{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intervention+II&page=112",
    "query": {
      "intervention": "Intervention II",
      "page": 112
    },
    "page_size": 10
  },
  "pagination": {
    "page": 112,
    "page_size": 10,
    "total_count": 3478,
    "total_pages": 348,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intervention+II&page=113&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intervention+II&page=111&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T01:02:31.812Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01256398",
      "title": "Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1"
      ],
      "interventions": [
        {
          "name": "Alemtuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Etoposide Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "In Vitro-Treated Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Mercaptopurine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2010-12-14",
      "completion_date": "2021-11-15",
      "has_results": true,
      "last_update_posted_date": "2023-04-04",
      "last_synced_at": "2026-11-18T01:02:31.812Z",
      "location_count": 101,
      "location_summary": "Palo Alto, California • Aurora, Colorado • Boulder, Colorado + 68 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01256398"
    },
    {
      "nct_id": "NCT03137693",
      "title": "Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Cancer Female",
        "Breast Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Standard of Care Schedule Variation: SABR",
          "type": "OTHER"
        },
        {
          "name": "Breast-conserving Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "50 Years and older · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2017-11-29",
      "completion_date": "2020-01-27",
      "has_results": true,
      "last_update_posted_date": "2023-02-23",
      "last_synced_at": "2026-11-18T01:02:31.812Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03137693"
    },
    {
      "nct_id": "NCT04739800",
      "title": "Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fallopian Tube Mucinous Adenocarcinoma",
        "Ovarian Seromucinous Carcinoma",
        "Platinum-Refractory Fallopian Tube Carcinoma",
        "Platinum-Refractory Ovarian Carcinoma",
        "Platinum-Refractory Primary Peritoneal Carcinoma",
        "Recurrent Fallopian Tube Clear Cell Adenocarcinoma",
        "Recurrent Fallopian Tube Endometrioid Adenocarcinoma",
        "Recurrent Fallopian Tube High Grade Serous Adenocarcinoma",
        "Recurrent Fallopian Tube Mucinous Adenocarcinoma",
        "Recurrent Fallopian Tube Transitional Cell Carcinoma",
        "Recurrent Fallopian Tube Undifferentiated Carcinoma",
        "Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma",
        "Recurrent Ovarian Clear Cell Adenocarcinoma",
        "Recurrent Ovarian Endometrioid Adenocarcinoma",
        "Recurrent Ovarian High Grade Serous Adenocarcinoma",
        "Recurrent Ovarian Low Grade Serous Adenocarcinoma",
        "Recurrent Ovarian Mucinous Adenocarcinoma",
        "Recurrent Ovarian Seromucinous Carcinoma",
        "Recurrent Ovarian Transitional Cell Carcinoma",
        "Recurrent Ovarian Undifferentiated Carcinoma",
        "Recurrent Platinum-Resistant Fallopian Tube Carcinoma",
        "Recurrent Platinum-Resistant Ovarian Carcinoma",
        "Recurrent Platinum-Resistant Primary Peritoneal Carcinoma",
        "Recurrent Primary Peritoneal Clear Cell Adenocarcinoma",
        "Recurrent Primary Peritoneal Endometrioid Adenocarcinoma",
        "Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma",
        "Recurrent Primary Peritoneal Transitional Cell Carcinoma",
        "Recurrent Primary Peritoneal Undifferentiated Carcinoma",
        "Refractory Fallopian Tube Clear Cell Adenocarcinoma",
        "Refractory Fallopian Tube Endometrioid Adenocarcinoma",
        "Refractory Fallopian Tube High Grade Serous Adenocarcinoma",
        "Refractory Fallopian Tube Mucinous Adenocarcinoma",
        "Refractory Fallopian Tube Transitional Cell Carcinoma",
        "Refractory Fallopian Tube Undifferentiated Carcinoma",
        "Refractory Low Grade Fallopian Tube Serous Adenocarcinoma",
        "Refractory Ovarian Clear Cell Adenocarcinoma",
        "Refractory Ovarian Endometrioid Adenocarcinoma",
        "Refractory Ovarian High Grade Serous Adenocarcinoma",
        "Refractory Ovarian Low Grade Serous Adenocarcinoma",
        "Refractory Ovarian Mucinous Adenocarcinoma",
        "Refractory Ovarian Seromucinous Carcinoma",
        "Refractory Ovarian Transitional Cell Carcinoma",
        "Refractory Ovarian Undifferentiated Carcinoma",
        "Refractory Primary Peritoneal Clear Cell Adenocarcinoma",
        "Refractory Primary Peritoneal Endometrioid Adenocarcinoma",
        "Refractory Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma",
        "Refractory Primary Peritoneal Transitional Cell Carcinoma",
        "Refractory Primary Peritoneal Undifferentiated Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cediranib Maleate",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography with Contrast",
          "type": "PROCEDURE"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Liposomal Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Topotecan Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 120,
      "start_date": "2021-06-10",
      "completion_date": "2027-06-25",
      "has_results": true,
      "last_update_posted_date": "2026-11-13",
      "last_synced_at": "2026-11-18T01:02:31.812Z",
      "location_count": 384,
      "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 288 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04739800"
    },
    {
      "nct_id": "NCT01205334",
      "title": "Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "GBM",
        "Brain Cancer"
      ],
      "interventions": [
        {
          "name": "Autologous CMV-specific CTL",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 2,
      "start_date": "2010-11",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2013-08-26",
      "last_synced_at": "2026-11-18T01:02:31.812Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01205334"
    },
    {
      "nct_id": "NCT00729612",
      "title": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel albumin-stabilized nanoparticle formulation",
          "type": "DRUG"
        },
        {
          "name": "protein expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "immunoenzyme technique",
          "type": "OTHER"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "Greg Otterson",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 63,
      "start_date": "2008-08-14",
      "completion_date": "2011-12-16",
      "has_results": true,
      "last_update_posted_date": "2018-04-02",
      "last_synced_at": "2026-11-18T01:02:31.812Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00729612"
    },
    {
      "nct_id": "NCT02294565",
      "title": "VST-1001 (Dilute Fluorescein) for Lymphatic Mapping & Localization of Lymph Nodes in Patients With Breast Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "VST-1001",
          "type": "DRUG"
        },
        {
          "name": "99mTc-labeled sulfur colloid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vestan, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 147,
      "start_date": "2014-06",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2015-07-27",
      "last_synced_at": "2026-11-18T01:02:31.812Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02294565"
    },
    {
      "nct_id": "NCT04415944",
      "title": "Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Epithelial Cancer Stage I",
        "Ovarian Epithelial Cancer Stage II",
        "Ovarian Epithelial Cancer Stage III",
        "Stage I Fallopian Tube Cancer",
        "Stage II Fallopian Tube Cancer",
        "Stage III Fallopian Tube Cancer",
        "Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Second look laparoscopy reassessment surgery (SLLRS)",
          "type": "PROCEDURE"
        },
        {
          "name": "HIPEC with Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "FACT-O Quality of Life Questionnaire",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2021-05-20",
      "completion_date": "2026-01-23",
      "has_results": true,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-11-18T01:02:31.812Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04415944"
    },
    {
      "nct_id": "NCT00827099",
      "title": "Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "umbilical cord blood transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Northside Hospital, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 5,
      "start_date": "2006-06",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2012-03-23",
      "last_synced_at": "2026-11-18T01:02:31.812Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00827099"
    },
    {
      "nct_id": "NCT05361798",
      "title": "A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer Of Prostate"
      ],
      "interventions": [
        {
          "name": "PDS01ADC",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic Body Radiation Therapy (SBRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 65,
      "start_date": "2023-06-12",
      "completion_date": "2027-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-11-18T01:02:31.812Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05361798"
    },
    {
      "nct_id": "NCT05469893",
      "title": "Immuno-PRISM (PRecision Intervention Smoldering Myeloma)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High-risk Smoldering Multiple Myeloma",
        "Smoldering Multiple Myeloma",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Teclistamab",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Irene Ghobrial, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2022-08-10",
      "completion_date": "2030-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-11-18T01:02:31.812Z",
      "location_count": 3,
      "location_summary": "Denver, Colorado • Boston, Massachusetts • Portland, Oregon",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05469893"
    }
  ]
}